Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $0.250 $0.685 Friday, 10th May 2024 ADXS stock ended at $0.437. This is 21.96% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 108.00% from a day low at $0.250 to a day high of $0.520.
90 days $0.250 $1.05
52 weeks $0.250 $1.95

Historical Advaxis prices

Date Open High Low Close Volume
Nov 28, 2016 $141.60 $143.10 $133.50 $133.50 32 548
Nov 25, 2016 $144.75 $145.20 $139.50 $142.80 16 254
Nov 23, 2016 $139.65 $147.90 $135.75 $144.00 43 518
Nov 22, 2016 $149.40 $150.00 $143.40 $145.50 25 152
Nov 21, 2016 $147.00 $151.50 $146.70 $148.80 28 725
Nov 18, 2016 $145.80 $147.90 $143.25 $147.00 26 071
Nov 17, 2016 $146.55 $149.40 $143.10 $146.40 23 339
Nov 16, 2016 $150.75 $159.75 $146.55 $147.30 54 090
Nov 15, 2016 $146.25 $151.50 $136.65 $150.45 76 059
Nov 14, 2016 $150.75 $151.50 $146.25 $147.45 54 983
Nov 11, 2016 $157.80 $160.35 $149.40 $151.80 54 212
Nov 10, 2016 $150.60 $163.20 $148.65 $154.50 54 990
Nov 09, 2016 $146.25 $154.20 $145.05 $152.10 58 863
Nov 08, 2016 $141.90 $141.90 $141.90 $141.90 52 000
Nov 07, 2016 $138.75 $138.75 $138.75 $138.75 69 020
Nov 04, 2016 $129.00 $129.00 $129.00 $129.00 72 720
Nov 03, 2016 $115.65 $115.65 $115.65 $115.65 44 800
Nov 02, 2016 $123.15 $123.15 $123.15 $123.15 54 513
Nov 01, 2016 $129.75 $129.75 $129.75 $129.75 85 287
Oct 31, 2016 $121.35 $121.35 $121.35 $121.35 23 660
Oct 28, 2016 $120.30 $120.30 $120.30 $120.30 42 007
Oct 27, 2016 $118.05 $118.05 $118.05 $118.05 42 393
Oct 26, 2016 $123.60 $123.60 $123.60 $123.60 34 667
Oct 25, 2016 $126.00 $126.00 $126.00 $126.00 43 473
Oct 24, 2016 $132.15 $132.15 $132.15 $132.15 98 147
Click to get the best stock tips daily for free!

About Advaxis

Advaxis Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for... ADXS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT